OSL · NYKD.OL
Nykode Therapeutics AS
NOK 3.06+NOK 0.04 (+1.16%)
Nykode Therapeutics AS’s quoted price sits in the lower half of its reported 52-week range, 41.25% below the high.
Loading market information…
OSL · CONTX.OL · NOK
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:18 AM UTC. Cached market data; not a live quote.
One-year closing-price history · NOK. Historical prices are not a forecast.
ContextVision AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 24.39% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
ContextVision AB (publ)’s forward annual dividend is NOK 0.31 per share, paid semi-annual. The forward yield is 7.0% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
ContextVision AB (publ)’s next earnings report is currently expected on Nov 5, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ContextVision AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ContextVision AB (publ), a medical technology enterprise established in Stockholm, Sweden, in 1983, delivers sophisticated software solutions. The firm specializes in image analysis and artificial intelligence, supplying these advanced technologies to original equipment manufacturers (OEMs) across Asia, Europe, and the United States. Their comprehensive product suite is designed to optimize image quality across various medical imaging modalities, including two-dimensional, three-dimensional, and four-dimensional ultrasound, radiography, magnetic resonance imaging (MRI), and mammography. Key offerings include: Rivent: Provides superior image quality for a broad spectrum of ultrasound applications such as women's health, general imaging, cardiovascular, and point-of-care. VolarView: An image enhancement software specifically developed for the burgeoning handheld ultrasound market. GOPiCE: A proprietary technology enabling real-time volumetric image enhancement. Altumira/Altumira Plus: A robust platform for digital radiography. An Orthopedic Package: Tailored for specialized orthopedic imaging needs. GOPView MRI2Plus: An advanced solution for MRI image improvement. INIFY Prostate Screening: Offers digital analysis for prostate biopsies.
Latest available per-share figures in NOK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:35 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| NOK 27.46M-27.15% vs estimate |
| Q4 2024 | Feb 20, 2025 | NOK 0.11+37.46% vs estimate | NOK 34.95M+10.0% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | NOK 0.070.0% vs estimate | NOK 31.21M-1.95% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NOK 3.06+NOK 0.04 (+1.16%)
Nykode Therapeutics AS’s quoted price sits in the lower half of its reported 52-week range, 41.25% below the high.
NOK 38.60NOK 0.00 (0.0%)
Gentian Diagnostics AS’s quoted price sits in the lower half of its reported 52-week range, 35.67% below the high.
NOK 7.74+NOK 0.24 (+3.2%)
Lytix Biopharma AS’s quoted price sits in the lower half of its reported 52-week range, 34.96% below the high.
NOK 1.30NOK 0.00 (0.0%)
Hofseth BioCare ASA’s quoted price sits in the lower half of its reported 52-week range, 37.14% below the high.
NOK 11.25+NOK 0.25 (+2.27%)
Navamedic ASA’s quoted price sits in the lower half of its reported 52-week range, 57.55% below the high.
NOK 0.44+NOK 0.01 (+2.69%)
Lifecare AS’s quoted price sits in the lower half of its reported 52-week range, 92.81% below the high.
NOK 5.00-NOK 0.20 (-3.85%)
CodeLab Capital AS’s quoted price sits in the upper half of its reported 52-week range, 18.83% below the high.
NOK 2.28+NOK 0.08 (+3.64%)
Arctic Bioscience AS’s quoted price sits in the lower half of its reported 52-week range, 45.71% below the high.
